These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32169380)

  • 1. Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen.
    Larson D; Patel P; Salapatek AM; Couroux P; Whitehouse D; Pina A; Johnson JL; Sever ML; Sanda S; Poyser J; Allio T; Scadding GW; Qin T; Shamji MH; Kwok WW; James EA; French D; Lelic A; Larché M; Altman MC; Togias A; Durham SR
    J Allergy Clin Immunol; 2020 Jun; 145(6):1585-1597. PubMed ID: 32169380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local and systemic effects of cat allergen nasal provocation.
    Scadding GW; Eifan A; Penagos M; Dumitru A; Switzer A; McMahon O; Phippard D; Togias A; Durham SR; Shamji MH
    Clin Exp Allergy; 2015 Mar; 45(3):613-23. PubMed ID: 25303516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.
    Eckman JA; Sterba PM; Kelly D; Alexander V; Liu MC; Bochner BS; Macglashan DW; Saini SS
    J Allergy Clin Immunol; 2010 Apr; 125(4):889-895.e7. PubMed ID: 19962744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of airway responses to cat allergen: comparison of environmental challenge to quantitative nasal and bronchial allergen challenge.
    Sicherer SH; Wood RA; Eggleston PA
    J Allergy Clin Immunol; 1997 Jun; 99(6 Pt 1):798-805. PubMed ID: 9215248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeatability of nasal allergen challenge results: Further validation of the allergic rhinitis clinical investigator collaborative protocols.
    Soliman M; Steacy LM; Thiele J; Adams DE; Neighbour HL; Ellis AK
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):607-613. PubMed ID: 29432965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge.
    Scadding GW; Eifan AO; Lao-Araya M; Penagos M; Poon SY; Steveling E; Yan R; Switzer A; Phippard D; Togias A; Shamji MH; Durham SR
    Allergy; 2015 Jun; 70(6):689-96. PubMed ID: 25773990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract.
    Nanda A; O'connor M; Anand M; Dreskin SC; Zhang L; Hines B; Lane D; Wheat W; Routes JM; Sawyer R; Rosenwasser LJ; Nelson HS
    J Allergy Clin Immunol; 2004 Dec; 114(6):1339-44. PubMed ID: 15577832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cat allergen-induced blood basophil reactivity in vitro predicts acute human nasal allergen challenge responses in vivo.
    Paterniti M; Kelly DC; Eckman JA; Sterba PM; Hamilton RG; Bochner BS; Macglashan DW; Saini SS
    Clin Exp Allergy; 2011 Jul; 41(7):963-9. PubMed ID: 21668817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure.
    Badorrek P; Müller M; Koch W; Hohlfeld JM; Krug N
    Ann Allergy Asthma Immunol; 2017 Mar; 118(3):290-297. PubMed ID: 28284536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
    Shamji MH; Singh I; Layhadi JA; Ito C; Karamani A; Kouser L; Sharif H; Tang J; Handijiev S; Parkin RV; Durham SR; Kostic A; Orengo JM; DeVeaux M; Kamal M; Stahl N; Yancopoulos GD; Wang CQ; Radin AR
    Am J Respir Crit Care Med; 2021 Jul; 204(1):23-33. PubMed ID: 33651675
    [No Abstract]   [Full Text] [Related]  

  • 12. Effector cell signature in peripheral blood following nasal allergen challenge in grass pollen allergic individuals.
    Shamji MH; Bellido V; Scadding GW; Layhadi JA; Cheung DK; Calderon MA; Asare A; Gao Z; Turka LA; Tchao N; Togias A; Phippard D; Durham SR
    Allergy; 2015 Feb; 70(2):171-9. PubMed ID: 25377909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of acoustic rhinometry in assessing nasal responses to cat exposure.
    Phipatanakul W; Kesavanathan J; Eggleston PA; Johnson EF; Wood RA
    J Allergy Clin Immunol; 1998 Dec; 102(6 Pt 1):896-901. PubMed ID: 9847428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhinoconjunctivitis severity induced by cat exposure influences early and late asthmatic responses: Evidence from an environmental exposure chamber.
    Piotin A; Godet J; Domis N; de Blay F
    Clin Exp Allergy; 2024 Aug; 54(8):596-606. PubMed ID: 38660824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical symptoms and biomarkers of Bermuda grass-induced allergic rhinitis using the nasal allergen challenge model.
    Rawls M; Thiele J; Adams DE; Steacy LM; Ellis AK
    Ann Allergy Asthma Immunol; 2020 Jun; 124(6):608-615.e2. PubMed ID: 32173484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions.
    Corren J; Rachelefsky G; Spector S; Schanker H; Siegel S; Holton D; Karcher K; Travers S
    J Allergy Clin Immunol; 1999 Apr; 103(4):574-80. PubMed ID: 10200003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy.
    Neighbour H; Soliman M; Steacy LM; Hickey P; Forbes B; Larché M; Ellis AK
    Clin Transl Allergy; 2018; 8():15. PubMed ID: 29682277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal IL-13 production identifies patients with late-phase allergic responses.
    Campion NJ; Villazala-Merino S; Thwaites RS; Stanek V; Killick H; Pertsinidou E; Zghaebi M; Toth J; Fröschl R; Perkmann T; Gangl K; Schneider S; Ristl R; Scott IC; Cohen ES; Molin M; Focke-Tejkl M; Regelsberger G; Hansel TT; Valenta R; Niederberger-Leppin V; Eckl-Dorna J
    J Allergy Clin Immunol; 2023 Nov; 152(5):1167-1178.e12. PubMed ID: 37536510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of allergic rhinitis outcomes of the environmental exposure unit and nasal allergen challenge model.
    Tenn MW; Steacy LM; Adams DE; Walker TJ; Ellis AK
    Ann Allergy Asthma Immunol; 2019 Jul; 123(1):105-106.e1. PubMed ID: 30959101
    [No Abstract]   [Full Text] [Related]  

  • 20. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract.
    Ewbank PA; Murray J; Sanders K; Curran-Everett D; Dreskin S; Nelson HS
    J Allergy Clin Immunol; 2003 Jan; 111(1):155-61. PubMed ID: 12532112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.